Thymosin Beta-4 Dosing & Reconstitution Guide

Thymosin Beta-4 can be administered via subcutaneous (SC) injection or through topical/ophthalmic routes. For subcutaneous administration, research indicates a frequency of once daily, with a typical dose range of 750 to 2000 mcg per day, depending on the specific research context and objectives. In studies exploring the ophthalmic application, such as with RGN-259, a 0.1% solution is recommended, with two drops administered twice daily. It is important to note that the dosing regimen may vary based on the specific experimental design and the goals of the research, underscoring the need for careful consideration of individual study parameters.

Clinical trials assessing the safety of RGN-259, an ophthalmic formulation of Thymosin Beta-4, reported that the solution was well-tolerated among participants, with no significant drug-related adverse events observed. Additionally, a safety-focused study involving 40 healthy adults receiving injectable Tβ4 found minimal adverse effects, suggesting a favorable safety profile in controlled settings. However, caution is warranted as certain contraindications exist. Individuals with active cancer or a history of cancer may face theoretical risks due to Tβ4's potential role in promoting cell migration. Furthermore, there is insufficient safety data regarding the systemic use of Tβ4 during pregnancy and breastfeeding, necessitating careful consideration in these populations.